Anagrelid

Anagrelid
Klinički podaci
Prodajno ime	Agrylin, Xagrid
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	1,3 h
Identifikatori
CAS broj	68475-42-3
ATC kod	L01XX35 (WHO)
PubChem	CID 2182
DrugBank	DB00261
ChemSpider	2097
ChEBI	CHEBI:142290
ChEMBL	CHEMBL760
Hemijski podaci
Formula	C10H7Cl2N3O
Molarna masa	256,088
	SMILES ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl; ;
	InChI InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) ; Key:OTBXOEAOVRKTNQ-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	280 °C (536 °F)

Anagrelid je organsko jedinjenje, koje sadrži 10 atoma ugljenika i ima molekulsku masu od 256,088 Da.^[1]^[2]^[3]^[4]^[5]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	0
Particioni koeficijent^[6] (ALogP)	2,0
Rastvorljivost^[7] (logS, log(mol/L))	-2,7
Polarna površina^[8] (PSA, Å²)	44,7

Reference

^ Voglova J, Maisnar V, Beranek M, Chrobak L: [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase] Voglová, J.; Maisnar, V.; Beránek, M.; Chrobák, L. (септембар 2006). . „Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase”. Vnitr Lek. 52 (9): 819—22. PMID 17091608.
^ Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. Petrides, P. E. (2006). . „Anagrelide: What was new in 2004 and 2005?”. Seminars in Thrombosis and Hemostasis. 32 (4 Pt 2): 399—408. PMID 16810615. doi:10.1055/s-2006-942760.
^ Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (јул 2005). . „Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia”. N Engl J Med. 353 (1): 33—45. PMID 16000354. doi:10.1056/NEJMoa043800.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Anagrelide

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Voglova J, Maisnar V, Beranek M, Chrobak L: [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase] Voglová, J.; Maisnar, V.; Beránek, M.; Chrobák, L. (септембар 2006). . „Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase”. Vnitr Lek. 52 (9): 819—22. PMID 17091608.

[2] Petrides PE: Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):399-408. Petrides, P. E. (2006). . „Anagrelide: What was new in 2004 and 2005?”. Seminars in Thrombosis and Hemostasis. 32 (4 Pt 2): 399—408. PMID 16810615. doi:10.1055/s-2006-942760.

[3] Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (јул 2005). . „Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia”. N Engl J Med. 353 (1): 33—45. PMID 16000354. doi:10.1056/NEJMoa043800.

[4] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[5] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[6] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[7] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[8] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

p r u Citostatici-antitumorski lekovi
Alkilirajuća sredstva	ciklofosfamid • ifosfamid • temozolomid • dakarbazin
Antimetaboliti	metotreksat • pemetreksed • kladribin • fludarabin • citarabin • fluorouracil • gemcitabin • kapecitabin
Protivtumorski antibiotici	doksorubicin • daunorubicin • idarubicin • bleomicin
Sredastva biljnog porekla	vinblastin • vinkristin • vinorelbin • etopozid • paklitaksel • docetaksel
Hormonski lekovi	megestrol • medroksiprogesteron • goserelin • triptorelin • tamoksifen • flutamid • nilutamid • bikalutamid • anastrozol • letrozol • eksemestan
Ostali najnoviji lekovi	cisplatin • karboplatin • oksaliplatin • rituksimab • alemtuzumab • cetuksimab • bevacizumab • imatinib • gefitinib • erlotinib • sorafenib • estramustin • tretinoin • bortezomib • anagrelid